Exelixis (EXEL) Other Operating Expenses (2010 - 2026)
Exelixis (EXEL) posted quarterly Other Operating Expenses of $20.0 million for Q2 2026, up 4.07% year-over-year from $19.2 million in Q2 2025, and down 24.65% quarter-over-quarter from $26.5 million in Q1 2026.
Analysis
Exelixis (EXEL) Other Operating Expenses (2010 - 2026) Analysis & Trends
Exelixis' Other Operating Expenses history runs 16 years deep, the most recent figure standing at $20.0 million for Q2 2026.
- In Q2 2026, Other Operating Expenses rose 4.07% year-over-year to $20.0 million; the TTM figure through Apr 2026 stood at $84.5 million (down 32.83% YoY), while the FY2026 annual figure was $83.7 million, down 34.53% from the prior year.
- Other Operating Expenses for Q2 2026 stood at $20.0 million, down from $26.5 million in the prior quarter.
- The five-year high for Other Operating Expenses was $69.0 million in Q3 2024, with the low at $13.2 million in Q2 2022.
- The 5-year median for Other Operating Expenses is $18.8 million (2023), against an average of $21.3 million.
- The sharpest annual moves came in 2022 and 2024: Other Operating Expenses tumbled 91.16% in 2022, then jumped 267.53% in 2024.
- Exelixis' Other Operating Expenses stood at $15.9 million in 2022, then jumped by 36.64% to $21.8 million in 2023, then surged by 217.2% to $69.0 million in 2024, then tumbled by 73.08% to $18.6 million in 2025, then climbed by 7.42% to $20.0 million in 2026.
- Business Quant data shows EXEL's Other Operating Expenses at $20.0 million in Q2 2026, $26.5 million in Q1 2026, and $18.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 20.66 Mn |
| Apr 3, 2026 | 19.95 Mn |
| Jan 2, 2026 | 26.48 Mn |
| Oct 3, 2025 | 18.57 Mn |
| Jul 4, 2025 | 19.47 Mn |
| Apr 4, 2025 | 19.17 Mn |
| Jan 3, 2025 | 19.93 Mn |
| Sep 27, 2024 | 69.00 Mn |
| Jun 28, 2024 | 17.67 Mn |
| Mar 29, 2024 | 21.26 Mn |
| Dec 29, 2023 | 21.75 Mn |
| Sep 29, 2023 | 18.77 Mn |
| Jun 30, 2023 | 17.71 Mn |
| Mar 31, 2023 | 14.32 Mn |
| Dec 30, 2022 | 15.92 Mn |
| Sep 30, 2022 | 15.31 Mn |
| Jul 1, 2022 | 13.48 Mn |
| Apr 1, 2022 | 13.20 Mn |
| Dec 31, 2021 | 180.19 Mn |
| Oct 1, 2021 | 11.87 Mn |